The retergovir tablet of Merck is the first HIV integrase strand transfer inhibitors, also known as mk-0518. It can be used in combination with other antiretroviral drugs to treat human immunodeficiency virus (HIV) - 1 infection. It slows down the occurrence of HIV-1 infection by inhibiting HIV integrase required for virus replication.
Properties
Summary
Brief introduction Merck's retergovir tablet is the first HIV integrase strand transfer inhibitors, also known as mk-0518. It can be used in combination with other antiretroviral drugs to treat human immunodeficiency virus (HIV) - 1 infection. It slows down the occurrence of HIV-1 infection by inhibiting HIV integrase required for virus replication.